Closure of patent foramen ovale reduces the frequency of migraine attacks – (06-10-04)



Closure of patent foramen ovale reduces the frequency of migraine attacks

I’m finding this article very interesting. Fixing a patent foramen ovale (this is an opening from right to left ventricle that bypasses the lungs in the fetus who does not use the lungs, this should shut at birth) cuts migraine frequency in these patients by HALF. This really opens up a can of worms here. I’ve always had a problem with mainstream medicine’s approach to headaches in general. There is almost always an underlying physiological or anatomical imbalance that creates headaches. This needs to be found and fixed NOT COVERED UP WITH PAIN MEDS!!!! I cannot tell you how many times patients come into my office after years of unsuccessful treatment of headaches from the medical community and they are gone in 2-3 weeks.

This article would suggest that some degree of oxygen deprivation (patent foramen ovale leads to some blood skipping the lungs) was a major contributor to these patient’s migraines. Might some degree of this be present in patients without PDA? Maybe approaches designed to improve oxygenation, oxygen delivery and facilitate efficient use of the oxygen that is there might show strong benefits in migraine patients.

Neurology — Abstracts: Schwerzmann et al. 62 (8): 1399

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Migraine
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”